Collaboration Details

Print  Close


Title of Collaborative Activity:

P63, P13K and RAS oncogenes in tumorigenesis, immune deregulation and therapy of squamous cell carcinoma

Description of Collaborative Activity:

At the Food and Drug Administration (FDA), Dr. Weinberg is transducing murine keratinocytes with combinations of oncogenes found in human squamous cell carcinomas to determine if they generate transformation and tumors in laboratory conditions. Dr. Van Waes’ laboratory at the National Institute on Deafness and Other Communication Disorders (NIDCD) will study how these oncogene-driven tumors in mice deregulate keratinocytes and host immune responses, as well as response to various standard, molecular, and immune therapies.

Type of Collaborative Activity:

Research Initiative

Year the Collaborative Activity Originated:

2014

NIH Participating Institutes/Centers/Office of the Director:

NIDCD

HHS Agency Collaborators on this Activity:

FDA